100% tevredenheidsgarantie Direct beschikbaar na betaling Zowel online als in PDF Je zit nergens aan vast
logo-home
Samenvatting Lecture 7 - Clinical Trials and Clinical Development AM_1180 (AM_1180) €2,99
In winkelwagen

Samenvatting

Samenvatting Lecture 7 - Clinical Trials and Clinical Development AM_1180 (AM_1180)

 10 keer bekeken  0 keer verkocht

De hoorcollege is volledig samengevat

Voorbeeld 2 van de 9  pagina's

  • 2 februari 2023
  • 9
  • 2022/2023
  • Samenvatting
Alle documenten voor dit vak (8)
avatar-seller
GuusJan1
Lecture 7
Introduction→ if CRO is doing a trial for the sponsor, inspection finds both CRO and
sponsor are responsible.

The regulated world of clinical trials→ world is highly regulated on different levels:
 Global regulations → Guidelines: need to be put in law to have legally binding effect
 Regional regulations → EU Directives
 National regulations → Local law

Aim of drug development process→ obtain MAA (marketing authorization application):
 Results in a license to market an IP in a particular country or region
 Defines quality, permitted uses and restrictions
 Restricts also promotional claims.
 Defines packaging and labeling

Steps in acquiring an MAA
1. Preparation (takes significant amount of time)
2. Submission
3. Review by authorities (might take up to 2 years)
4. Inspections
5. Questions and answer (sponsor asks questions)

There are 3 ways (procedure) to get MAA in EU
1. Mutual recognition → submitted to one member state, others will mutually recognize
that decision when receiving a submission at a later time. So the review process is
performed 1 time only.
2. Centralized submission in the entire EU → submit centrally for EU authorization, in all
Member states at the same time, the EMA reviews it. Contains a difference:
 Mutual recognition only gives approval for the country you submitted.
Company decides mutual recognition when it cannot export enough product
to the entire EU (after EMA approval, you need to be able to produce as
many product as needed.
 EMA gives approval to use in the entire EU.
3. National fillings only available for local products or some line extensions.

Code of federal regulations (CFR), FDA tasks
 New product review (food, drugs & cosmetics).
 Post-marketing surveillance.
 Setting standards and writing regulations (CFR) → manufacturing, distribution,
labeling, proving safety and efficacy.
 Scientific research
 Regulatory enforcement and corrective action (black list). For drug research and
cosmetics, the FDA puts the guidelines into regulations within the US.

FDA-CFR→ data from outside the USA are not required by CFR in order to obtain
approval. However, advantages of international trials are:
 Higher number of potential subjects (shortens time, statistical consideration).
 Higher marketing advantages→ region where you want to submit, you use their
population.




1

, FDA types of applications
 They first work with: investigational new drug (IND) application → gives approval to
do research with that product in the US, product is not yet on market.
o Normal track
o Fast track (for pandemic or ethical reasons like cancer therapy). Only a
couple of years instead of average 12. Product may pass to phase 2 with only
1 trial
 New drug application (NDA): US version of MAA,
o Also normal or fast track procedure.
o Abbreviation New Drug Application (ANDA) → using for generics,
bioequivalents, but you don't need to go to the same process so it's quicker
for marketing approval.




 The IND triangle lies at the end of preclinical study, prior to clinical study every trial
needs to be approved. In the US you need an IND in place, you keep IND valid by
resubmitting CDP once something changes. Different in EU: need to get approval for
each trial.

FDA – NDA contains FDA – IND application contains
All known information about the compound All known information about the compound
Preclinical results Preclinical results
Clinical results Clinical results
Relevant marketing data Description of CDP
Manufacturing details Investigator's brochure (IB)
ANDA for generics & bioequivalents Qualifications of participating investigators
FDA needs 6 months to review FDA needs 30 days to review




2

Voordelen van het kopen van samenvattingen bij Stuvia op een rij:

Verzekerd van kwaliteit door reviews

Verzekerd van kwaliteit door reviews

Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!

Snel en makkelijk kopen

Snel en makkelijk kopen

Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.

Focus op de essentie

Focus op de essentie

Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!

Veelgestelde vragen

Wat krijg ik als ik dit document koop?

Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.

Tevredenheidsgarantie: hoe werkt dat?

Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.

Van wie koop ik deze samenvatting?

Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper GuusJan1. Stuvia faciliteert de betaling aan de verkoper.

Zit ik meteen vast aan een abonnement?

Nee, je koopt alleen deze samenvatting voor €2,99. Je zit daarna nergens aan vast.

Is Stuvia te vertrouwen?

4,6 sterren op Google & Trustpilot (+1000 reviews)

Afgelopen 30 dagen zijn er 53068 samenvattingen verkocht

Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen

Start met verkopen
€2,99
  • (0)
In winkelwagen
Toegevoegd